Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis.

Gentile A, Musella A, De Vito F, Rizzo FR, Fresegna D, Bullitta S, Vanni V, Guadalupi L, Stampanoni Bassi M, Buttari F, Centonze D, Mandolesi G.

Front Immunol. 2019 Sep 13;10:2197. doi: 10.3389/fimmu.2019.02197. eCollection 2019. Review.

2.

Reduced Annexin A1 Expression Associates with Disease Severity and Inflammation in Multiple Sclerosis Patients.

Colamatteo A, Maggioli E, Azevedo Loiola R, Hamid Sheikh M, Calì G, Bruzzese D, Maniscalco GT, Centonze D, Buttari F, Lanzillo R, Perna F, Zuccarelli B, Mottola M, Cassano S, Galgani M, Solito E, De Rosa V.

J Immunol. 2019 Oct 1;203(7):1753-1765. doi: 10.4049/jimmunol.1801683. Epub 2019 Aug 28.

PMID:
31462505
3.

Interleukin-6 Disrupts Synaptic Plasticity and Impairs Tissue Damage Compensation in Multiple Sclerosis.

Stampanoni Bassi M, Iezzi E, Mori F, Simonelli I, Gilio L, Buttari F, Sica F, De Paolis N, Mandolesi G, Musella A, De Vito F, Dolcetti E, Bruno A, Furlan R, Finardi A, Marfia GA, Centonze D, Rizzo FR.

Neurorehabil Neural Repair. 2019 Aug 20:1545968319868713. doi: 10.1177/1545968319868713. [Epub ahead of print]

PMID:
31431121
4.

The Characterization of Regulatory T-Cell Profiles in Alzheimer's Disease and Multiple Sclerosis.

Ciccocioppo F, Lanuti P, Pierdomenico L, Simeone P, Bologna G, Ercolino E, Buttari F, Fantozzi R, Thomas A, Onofrj M, Centonze D, Miscia S, Marchisio M.

Sci Rep. 2019 Jun 19;9(1):8788. doi: 10.1038/s41598-019-45433-3.

5.

Obesity worsens central inflammation and disability in multiple sclerosis.

Stampanoni Bassi M, Iezzi E, Buttari F, Gilio L, Simonelli I, Carbone F, Micillo T, De Rosa V, Sica F, Furlan R, Finardi A, Fantozzi R, Storto M, Bellantonio P, Pirollo P, Di Lemme S, Musella A, Mandolesi G, Centonze D, Matarese G.

Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473. [Epub ahead of print]

PMID:
31161863
6.

Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons.

Gentile A, De Vito F, Fresegna D, Rizzo FR, Bullitta S, Guadalupi L, Vanni V, Buttari F, Stampanoni Bassi M, Leuti A, Chiurchiù V, Marfia GA, Mandolesi G, Centonze D, Musella A.

Neuropathol Appl Neurobiol. 2019 May 24. doi: 10.1111/nan.12569. [Epub ahead of print]

PMID:
31125471
7.

Voluntary running wheel attenuates motor deterioration and brain damage in cuprizone-induced demyelination.

Mandolesi G, Bullitta S, Fresegna D, De Vito F, Rizzo FR, Musella A, Guadalupi L, Vanni V, Stampanoni Bassi M, Buttari F, Viscomi MT, Centonze D, Gentile A.

Neurobiol Dis. 2019 Sep;129:102-117. doi: 10.1016/j.nbd.2019.05.010. Epub 2019 May 14.

PMID:
31100354
8.

Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis.

Stampanoni Bassi M, Gentile A, Iezzi E, Zagaglia S, Musella A, Simonelli I, Gilio L, Furlan R, Finardi A, Marfia GA, Guadalupi L, Bullitta S, Mandolesi G, Centonze D, Buttari F.

Front Neurol. 2019 Jan 29;10:30. doi: 10.3389/fneur.2019.00030. eCollection 2019.

9.

Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.

Nicoletti CG, Monteleone F, Marfia GA, Usiello A, Buttari F, Centonze D, Mori F.

Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294. [Epub ahead of print]

PMID:
30730244
10.

Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression.

Stampanoni Bassi M, Gilio L, Maffei P, Dolcetti E, Bruno A, Buttari F, Centonze D, Iezzi E.

Front Mol Neurosci. 2018 Nov 20;11:424. doi: 10.3389/fnmol.2018.00424. eCollection 2018.

11.

Multiple Sclerosis: kFLC index values related to gender.

Pieri M, Zenobi R, Morello M, Storto M, Buttari F, Centonze D, Bernardini S, Dessi M.

Mult Scler Relat Disord. 2018 Nov;26:58-60. doi: 10.1016/j.msard.2018.08.018. Epub 2018 Aug 30.

PMID:
30223231
12.

Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course.

Stampanoni Bassi M, Iezzi E, Landi D, Monteleone F, Gilio L, Simonelli I, Musella A, Mandolesi G, De Vito F, Furlan R, Finardi A, Marfia GA, Centonze D, Buttari F.

J Neurol. 2018 Nov;265(11):2540-2547. doi: 10.1007/s00415-018-8994-5. Epub 2018 Aug 28.

PMID:
30167879
13.

Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions.

Musella A, Gentile A, Rizzo FR, De Vito F, Fresegna D, Bullitta S, Vanni V, Guadalupi L, Stampanoni Bassi M, Buttari F, Centonze D, Mandolesi G.

Front Aging Neurosci. 2018 Aug 8;10:238. doi: 10.3389/fnagi.2018.00238. eCollection 2018. Review.

14.

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.

Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6.

PMID:
29875218
15.

Tumor Necrosis Factor and Interleukin-1β Modulate Synaptic Plasticity during Neuroinflammation.

Rizzo FR, Musella A, De Vito F, Fresegna D, Bullitta S, Vanni V, Guadalupi L, Stampanoni Bassi M, Buttari F, Mandolesi G, Centonze D, Gentile A.

Neural Plast. 2018 May 14;2018:8430123. doi: 10.1155/2018/8430123. eCollection 2018. Review.

16.

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease.

Di Pardo A, Castaldo S, Amico E, Pepe G, Marracino F, Capocci L, Giovannelli A, Madonna M, van Bergeijk J, Buttari F, van der Kam E, Maglione V.

Hum Mol Genet. 2018 Jul 15;27(14):2490-2501. doi: 10.1093/hmg/ddy153.

PMID:
29688337
17.

Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis.

Stampanoni Bassi M, Iezzi E, Marfia GA, Simonelli I, Musella A, Mandolesi G, Fresegna D, Pasqualetti P, Furlan R, Finardi A, Mataluni G, Landi D, Gilio L, Centonze D, Buttari F.

J Neuroinflammation. 2018 Apr 14;15(1):108. doi: 10.1186/s12974-018-1150-4.

18.

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

PMID:
29549468
19.

The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis.

Farcomeni A, Cortese A, Sgarlata E, Alunni Fegatelli D, Marfia GA, Buttari F, Mirabella M, De Fino C, Prosperini L, Pozzilli C, Grasso MG, Iasevoli L, Di Battista G, Millefiorini E.

Neuroepidemiology. 2018;50(3-4):105-110. doi: 10.1159/000487005. Epub 2018 Mar 2.

PMID:
29502114
20.

Fingolimod reduces the clinical expression of active demyelinating lesions in MS.

Signoriello E, Landi D, Monteleone F, Saccà F, Nicoletti CG, Buttari F, Sica F, Marfia GA, Di Iorio G, Lus G, Centonze D.

Mult Scler Relat Disord. 2018 Feb;20:215-219. doi: 10.1016/j.msard.2018.02.002. Epub 2018 Feb 5.

PMID:
29433094
21.

Remodeling Functional Connectivity in Multiple Sclerosis: A Challenging Therapeutic Approach.

Stampanoni Bassi M, Gilio L, Buttari F, Maffei P, Marfia GA, Restivo DA, Centonze D, Iezzi E.

Front Neurosci. 2017 Dec 13;11:710. doi: 10.3389/fnins.2017.00710. eCollection 2017. Review.

22.

De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease.

Di Pardo A, Basit A, Armirotti A, Amico E, Castaldo S, Pepe G, Marracino F, Buttari F, Digilio AF, Maglione V.

Front Neurosci. 2017 Dec 19;11:698. doi: 10.3389/fnins.2017.00698. eCollection 2017.

23.

Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain.

Monteleone F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, Buttari F, Furlan R, Finardi A, Marfia GA, Centonze D, Mori F.

J Neuroimmunol. 2018 Jan 15;314:89-93. doi: 10.1016/j.jneuroim.2017.11.012. Epub 2017 Nov 20.

PMID:
29174194
24.

Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study.

Di Giuliano F, Albanese M, Picchi E, Mori F, Buttari F, Marfia GA, Garaci F, Mercuri NB, Floris R, Centonze D, Marziali S.

Radiol Med. 2018 Mar;123(3):202-208. doi: 10.1007/s11547-017-0829-4. Epub 2017 Nov 7.

PMID:
29116601
25.

Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.

Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Bargagli A; Multiple Sclerosis Study Group, Lazio Region.

Neuroepidemiology. 2017;48(3-4):171-178. doi: 10.1159/000479515. Epub 2017 Aug 9.

PMID:
28793295
26.

Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.

Landi D, Albanese M, Buttari F, Monteleone F, Boffa L, Rossi S, Motta C, Puma E, Centonze D.

PLoS One. 2017 Jul 7;12(7):e0165415. doi: 10.1371/journal.pone.0165415. eCollection 2017.

27.

KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.

Pieri M, Storto M, Pignalosa S, Zenobi R, Buttari F, Bernardini S, Centonze D, Dessi M.

J Neuroimmunol. 2017 Aug 15;309:31-33. doi: 10.1016/j.jneuroim.2017.05.007. Epub 2017 May 12.

PMID:
28601282
28.

Neurophysiology of synaptic functioning in multiple sclerosis.

Stampanoni Bassi M, Mori F, Buttari F, Marfia GA, Sancesario A, Centonze D, Iezzi E.

Clin Neurophysiol. 2017 Jul;128(7):1148-1157. doi: 10.1016/j.clinph.2017.04.006. Epub 2017 Apr 24. Review.

PMID:
28511127
29.

TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.

Buttari F, Zagaglia S, Marciano L, Albanese M, Landi D, Nicoletti CG, Mercuri NB, Silvestrini M, Provinciali L, Marfia GA, Mori F, Centonze D.

J Neuroimmunol. 2017 Apr 15;305:172-174. doi: 10.1016/j.jneuroim.2017.02.007. Epub 2017 Feb 8.

PMID:
28284340
30.

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group.

Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22.

31.

miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation.

Mandolesi G, De Vito F, Musella A, Gentile A, Bullitta S, Fresegna D, Sepman H, Di Sanza C, Haji N, Mori F, Buttari F, Perlas E, Ciotti MT, Hornstein E, Bozzoni I, Presutti C, Centonze D.

J Neurosci. 2017 Jan 18;37(3):546-561. doi: 10.1523/JNEUROSCI.0851-16.2016.

32.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22.

PMID:
27878443
33.

Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.

Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M.

J Neurol. 2016 Apr;263(4):751-9. doi: 10.1007/s00415-016-8049-8. Epub 2016 Feb 17.

34.

Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.

Albanese M, Zagaglia S, Landi D, Boffa L, Nicoletti CG, Marciani MG, Mandolesi G, Marfia GA, Buttari F, Mori F, Centonze D.

J Neuroinflammation. 2016 Feb 10;13:36. doi: 10.1186/s12974-016-0502-1.

35.

Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances.

Ghezzi A, Mutta E, Bianchi F, Bonavita S, Buttari F, Caramma A, Cavarretta R, Centonze D, Coghe GC, Coniglio G, Del Carro U, Ferrò MT, Marrosu MG, Patti F, Rovaris M, Sparaco M, Simone I, Tortorella C, Bergamaschi R.

Neurol Sci. 2016 Mar;37(3):437-42. doi: 10.1007/s10072-015-2415-7. Epub 2015 Nov 27.

PMID:
26613723
36.

Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis.

Gentile A, De Vito F, Fresegna D, Musella A, Buttari F, Bullitta S, Mandolesi G, Centonze D.

Front Cell Neurosci. 2015 Jun 25;9:243. doi: 10.3389/fncel.2015.00243. eCollection 2015.

37.

Epstein-Barr virus genetic variants are associated with multiple sclerosis.

Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D'Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D'Alfonso S, Pesole G, Salvetti M, Ristori G.

Neurology. 2015 Mar 31;84(13):1362-8. doi: 10.1212/WNL.0000000000001420. Epub 2015 Mar 4.

38.

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A.

Mult Scler. 2015 Nov;21(13):1713-22. doi: 10.1177/1352458515570768. Epub 2015 Feb 19.

PMID:
25698174
39.

CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis.

Mori F, Ljoka C, Nicoletti CG, Kusayanagi H, Buttari F, Giordani L, Rossi S, Foti C, Centonze D.

Neurol Neuroimmunol Neuroinflamm. 2014 Dec 11;1(4):e48. doi: 10.1212/NXI.0000000000000048. eCollection 2014 Dec.

40.

Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53.

Rossi S, Motta C, Studer V, Macchiarulo G, Volpe E, Barbieri F, Ruocco G, Buttari F, Finardi A, Mancino R, Weiss S, Battistini L, Martino G, Furlan R, Drulovic J, Centonze D.

Mol Neurodegener. 2014 Dec 12;9:56. doi: 10.1186/1750-1326-9-56.

41.

Reversible hyporegenerative anemia during natalizumab treatment.

Monteleone F, Buccisano F, Boffa L, Buttari F, Di Veroli A, Borriello G, Rossi S, Centonze D.

Mult Scler. 2015 Feb;21(2):257-8. doi: 10.1177/1352458514546516. Epub 2014 Sep 3. No abstract available.

PMID:
25186208
42.

Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.

Studer V, Rossi S, Motta C, Buttari F, Centonze D.

J Neuroimmunol. 2014 Nov 15;276(1-2):229-31. doi: 10.1016/j.jneuroim.2014.08.617. Epub 2014 Aug 19.

PMID:
25175066
43.

Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids.

Rossi S, Motta C, Studer V, Boffa L, De Chiara V, Castelli M, Barbieri F, Buttari F, Monteleone F, Germani G, Macchiarulo G, Weiss S, Centonze D.

CNS Neurosci Ther. 2014 Aug;20(8):748-53. doi: 10.1111/cns.12282. Epub 2014 May 19.

44.

Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosis.

Mori F, Nicoletti CG, Rossi S, Motta C, Kusayanagi H, Bergami A, Studer V, Buttari F, Barbieri F, Weiss S, Nisticò R, Martino G, Furlan R, Centonze D.

Neuromolecular Med. 2014 Jun;16(2):490-8. doi: 10.1007/s12017-014-8297-7. Epub 2014 Mar 27.

PMID:
24671722
45.

Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.

Rossi S, Studer V, Motta C, Germani G, Macchiarulo G, Buttari F, Mancino R, Castelli M, De Chiara V, Weiss S, Martino G, Furlan R, Centonze D.

J Neuroinflammation. 2014 Feb 18;11:32. doi: 10.1186/1742-2094-11-32.

46.

From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.

Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, Gasperini C.

Eur Neurol. 2014;71(5-6):233-41. doi: 10.1159/000356786. Epub 2014 Jan 25.

PMID:
24480868
47.

Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis.

Rossi S, Bozzali M, Bari M, Mori F, Studer V, Motta C, Buttari F, Cercignani M, Gravina P, Mastrangelo N, Castelli M, Mancino R, Nucci C, Sottile F, Bernardini S, Maccarrone M, Centonze D.

PLoS One. 2013 Dec 31;8(12):e82848. doi: 10.1371/journal.pone.0082848. eCollection 2013.

48.

Synaptic plasticity and PDGF signaling defects underlie clinical progression in multiple sclerosis.

Mori F, Rossi S, Piccinin S, Motta C, Mango D, Kusayanagi H, Bergami A, Studer V, Nicoletti CG, Buttari F, Barbieri F, Mercuri NB, Martino G, Furlan R, Nisticò R, Centonze D.

J Neurosci. 2013 Dec 4;33(49):19112-9. doi: 10.1523/JNEUROSCI.2536-13.2013.

49.

Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis.

Duranti F, Pieri M, Centonze D, Buttari F, Bernardini S, Dessi M.

J Neuroimmunol. 2013 Oct 15;263(1-2):116-20. doi: 10.1016/j.jneuroim.2013.07.006. Epub 2013 Aug 1.

PMID:
23916392
50.

Interleukin-1β promotes long-term potentiation in patients with multiple sclerosis.

Mori F, Nisticò R, Mandolesi G, Piccinin S, Mango D, Kusayanagi H, Berretta N, Bergami A, Gentile A, Musella A, Nicoletti CG, Nicoletti F, Buttari F, Mercuri NB, Martino G, Furlan R, Centonze D.

Neuromolecular Med. 2014 Mar;16(1):38-51. doi: 10.1007/s12017-013-8249-7. Epub 2013 Jul 28.

PMID:
23892937

Supplemental Content

Loading ...
Support Center